Global nuclear medicine market was estimated to be worth USD 9.25 billion in 2018 and is predicted to show lucrative growth in coming years. Rising number of procedures to diagnose and treat cancer is a key driver for the growth of nuclear medicine market globally. Nuclear diagnostics for elderly patients resulting in healthcare savings and nuclear medicine for improved pediatric survival rate are the other factors supporting the growth of nuclear medicine market.





However, competition from other imaging modalities, lack of patient and physician education and awareness may reduce the market penetration of nuclear medicines. Medical imaging is an extremely competitive market with nuclear medicines most expensive of the existing modalities. As a result, nuclear medicine's market is relatively constrained. The current market for nuclear diagnostics is saturated because nuclear diagnostics has failed to expand its patient and physician base. It has also failed to educate patients about the benefits of physiological imaging. The rival imaging modalities have been proactively accepted among medical practitioners and endorsed themselves to patients, nuclear medicine remains largely concealed from the mainstream. Thus, the potential of nuclear diagnostics remains unfulfilled. Educating medical practitioners and patients about the benefits of nuclear medicine can propagate and convince both groups of the economic benefits of nuclear medicine.

Nuclear medicines has been underutilized in many regions of the world. North America, dominated the nuclear medicines market in 2018, contributing USD 4.26 billion with U.S. a major consumer of nuclear medicines and Canada being the major supplier of the world radioisotopes. South America has been a slow growing market but is now realizing the potential of nuclear medicines and is thus expected to show lucrative growth during the forecast period. In the nuclear diagnostics market, PET and its hybrid modalities is expected to outpace SPECT analysis. Market players are concentrating in capacity addition to serve the growing demand of Technetium-99.

Key Segments of the Global Nuclear Medicine Market

Type Overview, 2015-2025 (USD Million) Technetium (Tc-99) Iodine (I-131) Fluorine (F-18) Lutetium (Lu-177) Yttrium (Y-90) Others

Diagnostics Overview, 2015-2025 (USD Million) PET ( Positron Emission Tomography) SPECT ( Single Photon Emission Computed Tomography)

Application Overview, 2015-2025 (USD Million) Oncology Neurology Cardiology Others

Regional Overview, 2015-2025 (USD Million) North America U.S. Canada Europe Germany UK France Russia Asia Pacific India China Japan Australia Rest of the World



Reasons for the study

Growing demand for radioisotopes in cancer imaging

Market players involved in capacity addition, for the production of radioisotopes

Nuclear diagnostics for older patients resulting in healthcare savings

Increasing application of Tc-99 in various medical procedures

What does the report include?

The study on the global nuclear medicine market includes qualitative factors such as drivers, restraints and opportunities

Additionally, the market has been evaluated using the Vendor Landscape Analysis and Value Chain Analysis.

The study covers qualitative and quantitative analysis of the market segmented on the basis of type, diagnostics, application and region. Moreover, the study provides similar information for the key geographies.

Actual market sizes and forecasts have been provided for all the above-mentioned segments

The study includes the profiles of key players in the market with a significant global and/or regional presence

Who should buy this report?

This study is suitable for industry participants and stakeholders in the nuclear medicine market. The report will benefit: